Biogen (NASDAQ:BIIB) Price Target Raised to $200.00

Biogen (NASDAQ:BIIB) had its price target upped by research analysts at Barclays from $185.00 to $200.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage presently has an “equal weight” rating on the biotechnology company’s stock. Barclays‘s price target suggests a potential downside of 2.73% from the company’s previous close.

A number of other brokerages have also recently issued reports on BIIB. Royal Bank Of Canada upped their target price on Biogen from $227.00 to $242.00 and gave the company an “outperform” rating in a research report on Tuesday, July 7th. Oppenheimer lifted their price target on Biogen from $275.00 to $300.00 and gave the stock an “outperform” rating in a research report on Thursday, May 14th. HC Wainwright reissued a “buy” rating on shares of Biogen in a report on Thursday, May 14th. Bank of America lowered their target price on shares of Biogen from $217.00 to $215.00 and set a “neutral” rating on the stock in a research report on Tuesday, July 21st. Finally, Morgan Stanley cut their target price on shares of Biogen from $224.00 to $222.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, twelve have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Biogen has a consensus rating of “Moderate Buy” and an average target price of $221.11.

Biogen Stock Up 2.7%

BIIB stock opened at $205.61 on Wednesday. The company has a current ratio of 3.06, a quick ratio of 2.41 and a debt-to-equity ratio of 0.34. Biogen has a twelve month low of $124.56 and a twelve month high of $219.72. The company’s 50 day moving average is $200.25 and its two-hundred day moving average is $190.21. The stock has a market cap of $30.36 billion, a P/E ratio of 22.06 and a beta of 0.16.

Biogen (NASDAQ:BIIB) last issued its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.94 by $0.66. The business had revenue of $2.74 billion during the quarter, compared to analysts’ expectations of $2.46 billion. Biogen had a net margin of 13.81% and a return on equity of 12.83%. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Research analysts expect that Biogen will post 11.28 earnings per share for the current fiscal year.

Institutional Trading of Biogen

Hedge funds have recently modified their holdings of the business. Reflection Asset Management acquired a new position in Biogen during the fourth quarter worth $25,000. WPG Advisers LLC increased its holdings in Biogen by 417.9% in the fourth quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 117 shares in the last quarter. First Horizon Corp acquired a new stake in shares of Biogen during the 4th quarter valued at approximately $30,000. WFA of San Diego LLC purchased a new stake in shares of Biogen during the 2nd quarter worth approximately $32,000. Finally, Root Financial Partners LLC boosted its stake in shares of Biogen by 198.4% during the 4th quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 123 shares in the last quarter. 87.93% of the stock is owned by institutional investors and hedge funds.

Key Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen reported second-quarter revenue of approximately $2.74 billion, up 3% year over year and ahead of the $2.46 billion analyst consensus. Adjusted EPS of $3.60 also exceeded expectations of $2.94. Biogen beats quarterly estimates as newer drugs fuel growth
• Positive Sentiment: The Growth Portfolio generated $1.06 billion in revenue, up 24% year over year and surpassing the legacy multiple-sclerosis portfolio. Key contributions included SKYCLARYS revenue of $168 million, ZURZUVAE revenue of $71 million, and post-acquisition sales from Apellis products SYFOVRE and EMPAVELI. Biogen Raises Earnings Guidance as Growth Portfolio Outpaces Legacy Blockbuster Drugs
• Positive Sentiment: Biogen expects 2026 revenue to increase by a mid-single-digit percentage, suggesting continued momentum from newer rare-disease and specialty medicines as older multiple-sclerosis products decline.
• Neutral Sentiment: The company completed its acquisition of Apellis, adding SYFOVRE and EMPAVELI to its commercial portfolio. The deal expands Biogen’s growth prospects but also introduces integration and execution risks.
• Negative Sentiment: GAAP net income fell to $97.5 million from $634.8 million a year earlier, while GAAP diluted EPS was $0.66. The decline highlights the impact of costs and other charges despite the adjusted earnings beat.
• Negative Sentiment: Biogen set full-year 2026 adjusted EPS guidance at $12.00-$13.00, below the $13.45 analyst consensus. The lower outlook is the main potential pressure on BIIB, even though quarterly results exceeded estimates. Biogen Cuts FY Adjusted View as Profit Declines

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.